Premium
Impetigo: A need for new therapies in a world of increasing antimicrobial resistance
Author(s) -
D'Cunha N. M.,
Peterson G. M.,
Baby K. E.,
Thomas J.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12639
Subject(s) - impetigo , antimicrobial , medicine , antibiotic resistance , antibiotics , intensive care medicine , skin infection , adverse effect , dermatology , anti infective agents , staphylococcus aureus , microbiology and biotechnology , bacteria , pharmacology , biology , genetics
Summary What is known and objective Impetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children. Antibiotics are the first‐line treatment when multiple lesions exist, but with an increasing prevalence of antibiotic‐resistant bacteria the successful management of impetigo in the future is an area of concern. Comment Current treatment options that favour the use of oral antibiotic therapy are increasingly problematic. Widespread use of these agents contributes to antimicrobial resistance and has adverse consequences for individuals and communities. There is a need for new topical antimicrobials and antiseptics as an alternative treatment strategy. What is new and conclusion To successfully treat impetigo into the future and ensure that therapy does not contribute to bacterial resistance, additional research is required to ascertain the usefulness of alternative agents, including new topical antimicrobials and antiseptics.